HIV-infected patients with lipodystrophy (HIV lipodystrophy) are insulin resistant and have elevated plasma free fatty acid (FFA) concentrations. We aimed to explore the mechanisms underlying FFA-induced insulin resistance in patients with HIV lipodystrophy. Using a randomized, placebo-controlled, cross-over design, we studied the effects of an overnight acipimox-induced suppression of FFAs on glucose and FFA metabolism by using stable isotopelabeled tracer techniques during basal conditions and a two-stage euglycemic-hyperinsulinemic clamp (20 and 50 mU insulin/m 2 per min, respectively) in nine patients with nondiabetic HIV lipodystrophy. All patients received antiretroviral therapy. Biopsies from the vastus lateralis muscle were obtained during each stage of the clamp. Acipimox treatment reduced basal FFA rate of appearance by 68.9% (95% CI 52.6 -79.5) and decreased plasma FFA concentration by 51.6% (42.0 -58.9) (both, P < 0.0001). Endogenous glucose production was not influenced by acipimox. During the clamp, the increase in glucose uptake was significantly greater after acipimox treatment compared with placebo (acipimox: 26. 85 , decreased phosphorylation of glycogen synthase (GS) site 3a ؉ b, and increased GS activity (percent I-form) in skeletal muscle (P < 0.01). Acipimox decreased phosphorylation of GS (site 3a ؉ b) (P < 0.02) and increased GS activity (P < 0.01) in muscle. The present study provides direct evidence that suppression of lipolysis in patients with HIV lipodystrophy improves insulin-stimulated peripheral glucose uptake. The increased glucose uptake may in part be explained by increased dephosphorylation of GS (site 3a ؉ b), resulting in increased GS activity.
H
IV-associated lipodystrophy (HIV lipodystrophy) is characterized by various degrees of subcutaneous fat loss, visceral fat accumulation, and metabolic disturbances, including peripheral and hepatic insulin resistance (1-3) and elevated plasma free fatty acids (FFAs) (4) . Increased plasma FFA concentration is due to increased lipolysis (5, 6) , with increased net release of FFAs from adipose tissue (5, 7) . In other insulin-resistant states (e.g., obesity and type 2 diabetes), increased rates of lipolysis and plasma FFA concentration are related to the degree of insulin resistance (8 -10) . Both acute and chronic suppression of lipolysis can improve insulin sensitivity in HIV lipodystrophy (11, 12) . However, the nature of improved insulin resistance (i.e., whether due to changes in hepatic or peripheral insulin sensitivity) has not been determined, and the molecular mechanism behind FFA-induced insulin resistance is still incompletely understood. FFAs have been proposed to induce skeletal muscle insulin resistance by inhibiting insulin-stimulated glucose transport/phosphorylation (13) (14) (15) (16) (17) and glycogen synthesis (13) (14) (15) (17) (18) (19) (20) .
Recently, it has been demonstrated that FFAs interfere with the proximal steps of the insulin signaling cascade by impairing the insulin-stimulated tyrosine phosphorylation of insulin receptor substrate (IRS)-1, IRS-1-associated phosphatidylinositol-3-kinase activity (13, 16, (21) (22) (23) (24) , and phosphorylation of Akt (Ser 473 and Thr 308 ) (21, 24) , resulting in decreased GLUT4 translocation to the plasma membrane. FFAs also influence the distal part of the insulin pathway. Previous studies (13) (14) (15) (17) (18) (19) consistently find that FFAs can reduce glycogen synthesis via inhibition of insulin-stimulated glycogen synthase (GS) activity, but the mechanism behind reduced GS activity is unknown (24) .
In HIV lipodystrophy, both oxidative and nonoxidative glucose metabolism are impaired (25) (26) (27) . A recent study (27) shows that patients with HIV lipodystrophy have a decreased insulin-stimulated GS activity in skeletal muscle. This defect in insulin action is associated with reduced dephosphorylation on sites 2 ϩ 2a, 3a, and 3a ϩ b, most likely via impaired signaling at the level of glycogen synthase kinase (GSK)-3␣ Ser 21 and GSK-3␤ Ser 9 and Akt but not further upstream at the level of IRS-1-associated phosphatidylinositol-3-kinase activity (27) . The present study aimed to explore the mechanisms underlying the increase in insulin sensitivity after acute suppression of lipolysis by acipimox in patients with HIV lipodystrophy and fasting hyperinsulinemia. We hypothesized that acipimox treatment would enhance insulin sensitivity by reducing endogenous glucose production and increasing peripheral glucose uptake. Furthermore, we hypothesized that increased insulin-stimulated peripheral glucose uptake would involve improved distal insulin signaling at the level of Akt, GSK-3, and GS in muscle.
RESEARCH DESIGN AND METHODS
Twenty-one HIV-positive men were recruited from the outpatient clinic of the Department of Infectious Disease (Rigshospitalet, Copenhagen, Denmark). Subjects underwent a medical examination, and standard blood tests were performed to determine eligibility. The following were the inclusion criteria: 1) Ͼ18 years of age; 2) stable antiretroviral (ARV) therapy, with no changes in ARV therapy during the preceding 8 weeks; and 3) fasting plasma insulin Ն104 pmol/l. If the fasting plasma insulin concentration was Ͻ104 mol/l, a standard 75-g oral glucose tolerance test was made and the subject was included if insulin levels were Ͼ521 mol/l after 120 min (11, 28) ; 4) lipoatrophy (at least one moderate sign of lipoatrophy [fat loss] in face, arms, buttocks, or legs based on a physical examination by a single investigator [B.L.]). The degree of lipoatrophy was rated as previously described (29) .
The exclusion criteria were 1) severe cardiovascular diseases; 2) hospitalization within the last 8 weeks; 3) fasting glucose Ն7 mmol/l; and 4) concurrent therapy with insulin, antidiabetes agents, testosterone, growth hormone, glucocorticoids, anabolic steroids, or anticoagulation. Of 21 patients who were recruited, 11 fulfilled the inclusion criteria and 2 declined to participate. Consequently, nine patients were included in the study. The following were reasons for exclusion: plasma insulin Ͻ104 mol/l (n ϭ 6), severe cardiovascular diseases (n ϭ 2), and no lipodystrophy by score (n ϭ 2). Two of six patients with plasma insulin Ͻ104 mol/l had lipodystrophy by the lipodystrophy score system. All patients received a combination of ARV therapies. All, except two, received protease inhibitors. Written informed consent was obtained according to the requirements from the local ethical committee. Body composition. Fat and fat-free tissue masses of the whole body, trunk, and extremities were measured using a dual-energy X-ray absorptiometry scanner (Norland XR 36, software version 3.94; Norland, Fort Atkinson, WI) (1). Stable isotope infusion study. The study was a randomized, double-blind, cross-over study. Each subject was studied twice (at least 2 weeks apart), once while receiving acipimox and once while receiving placebo (Fig. 1) . The ARV medication was taken 3.5-4.5 h before commencing the clamp, and the ARV combination was not changed throughout the study. Acipimox was administered in doses of 250 mg at 7:00 P.M. and 12:00 A.M. the night before and at 7:00 A.M. and 9:00 A.M. on the study day (30, 31) . At 7:00 A.M. on the study day after an overnight fast, an intravenous catheter was inserted into an antecubital vein of one arm for infusion of stable isotope-labeled tracers, insulin, and dextrose (20%). A second intravenous catheter was inserted into a hand vein of the contralateral arm, which was wrapped in a heating blanket to obtain arterialized blood samples. After baseline blood samples were obtained at 8 To determine glucose and palmitate concentrations and kinetics, arterialized blood samples were taken every 10 min during the last 30 min of the basal period and each stage of the insulin clamp (i.e., basal: 120, 130, 140, and 150 min; stage 1: 240, 250, 260, and 270 min; and stage 2: 480, 490, 500, and 510 min after the start of the tracer infusion) (3,32) (Fig. 1) . Venous blood samples were taken at 0, 30, 90, 120, 150, 180, 210, 240, 270, 300, 330, 390, 450, and 510 min. All blood samples were drawn into tubes containing EDTA and centrifuged. Plasma was stored at Ϫ80°C. Plasma concentration of FFAs and glycerol were determined using an automatic analyzer (Cobas fara; Roche, Basel, Switzerland; FFA: NEFA C; Wako Chemicals, Neuss, Germany). Insulin was measured by enzyme-linked immunosorbent assay (detection limit, 3.0 pg/ml; DakoCytomation, Cambridgeshire, U.K.). All determinations were run as duplicates, and mean values were calculated. To maintain euglycemia, arterialized blood glucose was measured every 5 min in the 1st hour of each clamp stage and every 10 min throughout the rest of the clamp and was analyzed immediately (EML 105 radiometer; Radiometer Medical A/S, Copenhagen, Denmark).
Total, HDL, and LDL cholesterol (mmol/l); triglycerides (mmol/l); and glucose (mmol/l) measurements on the day of inclusion were determined using standard laboratory procedures. CD4 ϩ cell counts were calculated by flow cytometry and HIV RNA copies (lower limit of detection: 20 copies/ml) were measured by the Amplicor HIV Monitor (Roche Molecular Systems, Branchburg, NJ).
Tracer analyses
Glucose. Enrichment of glucose was measured as previously described in detail (35) . In short, 20 l plasma was vigorously shaken with 100 l ethyl acetate to remove plasma lipids. After centrifugation (15,000 rpm at 5 min) the ethyl acetate was disposed and 20 l 8 mol NaOH, 1 mol K 2 HPO 4 , and 10 l benzoylchlorid were added, and the solution was vortexed for 5 min. After the vortex, the solution was naturalized by adding 10 l 1.4 H 3 PO 4 , and the glucose derivate, hexo-benzoyl glucose, was extracted by a short vigorous shake with 500 l ethylacetate. The ethylacete phase was separated by centrifugation and transferred to a new eppendorf tube, and the ethylacetate was evaporated under a stream of nitrogen. The glucose derivate was dissolved in the high-performance liquid chromatography buffer. The solution was filtered before being analyzed on the liquid chromotography-mass spectrometry system (aQa; Finnegan, Manchester, U.K.). Palmitate. Concentration and enrichment was determined by gas chromatography-mass spectrometry analysis (Automass II; Finnegan, Paris, France) as described by Patterson et al. (36) .
The fatty acid concentrations were determined by using an internal standard (1,2,3,4-13 C 4 -palmitic acid; Sigma Aldrich, MO), which was related to a standard curve. To determine plasma palmitate enrichment, the sample was separated on a 30-m capillary fused-silica column (Rtx-2330; Restex, Forney, TX) with an injector temperature at 50°C increased to 200°C at a rate of 20°C per min. The oven was set at the following program: initial 50°C increasing to 150°C at 10°C per min and then slowly increased to 163°C with a rate of 2°C per min. To clean the column, the temperature was increased to 260°C at a rate of 20°C per min and maintained at 260°C for 7 min. The mass spectrometer was scanned in a profile mode in a range from 287 to 311 amu. Calculations. Tracer-to-tracee ratios for both glucose and palmitate were calculated as the ratio between the master peak (M) and the enriched peak (M ϩ 2) after subtracting the background enrichment. The calculations are based on a steady-state assumption. For glucose the total rate of appearance (R a ) was calculated as the following:
and R d as the following:
where R a is rate of appearance (mol ⅐ kg body wt Ϫ1 ⅐ min Ϫ1 ). F total is the total infusion rate of glucose tracer (mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). E glucose is the enrichment of glucose in plasma (tracer-to-tracee ratio). GIR is the exogenous glucose administered during the clamp. R d is rate of disappearance (mol ⅐ kg body wt Ϫ1 ⅐ min Ϫ1 ). For palmitate, R a was calculated as the follwing:
where F is the infusion rate of 2 H 2 -palmitate (mol ⅐ kg body wt Ϫ1 ⅐ min Ϫ1 ) and E palmitate is the tracer-to-tracee ratio of plasma palmitate. The exact amount of tracer in the infusate was measured, as described above, for plasma palmitate concentration and enrichment, and this value was used in the calculation. R a is equal to R d during isotopic and physiologic steady state. SDS-PAGE and Western blotting. Muscle homogenate proteins were separated using 7.5% Bis-tris gels (Invitrogen, Taastrup, Denmark) and transferred (semidry) to polyvinylidine fluoride membranes (immobilon transfer membrane; Millipore, Glostrup, Denmark). After blocking (Tris-buffered saline with Tween with 2% skim milk), the membranes were incubated with primary antibodies (Tris-buffered saline with Tween with 2% skim milk) followed by incubation in horseradish peroxidase-conjugated secondary antibody (Trisbuffered saline with Tween with 2% skim milk) (Amersham Pharmacia Biotech, Buckinghamshire, U.K.). Following detection and quantification using a charge-coupled device image sensor and 1D software (Kodak Image Station, 2,000 mm; Kodak, Ballerup, Denmark), the protein content was finally expressed in arbitrary units relative to a human skeletal muscle standard. The antibodies used for detection of phosphorylation of AKT and GSK-3 were as follows: AKT Thr 308 (Upstate Biotechnology, Lake Placid, MA) and GSK-3␤ Ser 9 (ϳ35-kDa band using the anti-GSK-3␣/␤ Ser 21 /Ser 9 pan antibody; New England Biolabs, Beverly, MA). For detection of phosphorylation of glycogen synthase at site 3a ϩ 3b (Ser 640 ) and Ser 644 , an antibody raised in sheep, as described (37), was used. GS activity. GS activity was measured in muscle homogenates using a Unifilter 350 microtiter plate assay (Whatman, Frisenette, Ebeltoft, Denmark). The assay ran in triplicate based on the original protocol described by Thomas et al. (38) . GS activity was determined in the presence of 8 or 0.02 mmol/l glucose-6-phosphate (G6P), representing the maximal GS activity and the G6P-independent activity, respectively. The percent I-form of GS was calculated as 100 times the activity in the presence of 0.02 mmol/l G6P divided by the activity at 8.0 mmol/l G6P. Statistics. Values of FFAs, glycerol, R a , R d , and insulin were naturally log transformed to achieve homoscedacity and an approximate normal distribution. GS activity (I-form) and GSK-3␤ were analyzed with and without log transformation. Statistical analyses of substrate concentration and kinetics were carried out using a general linear mixed model. A random subjectspecific component was introduced that allowed adjusting for the interindividual variations. The effect of treatment was estimated using a binary variable (acipimox or placebo) and the effect of insulin infusion using a categorical variable (none, low [20 units/I], or high [50 units/I]) infusion level), and the model allowed for an interaction term between the two where needed. Time in minutes was entered as a continuous variable in the analysis of glucose, insulin, FFAs, and glycerol. Likelihood ratio tests were applied to assess statistical significance. The fit of the general linear model was evaluated by testing the residuals for normality and by inspection of the residual plots. Linear regression was used to quantify the proportion of the effect of increased dephosphorylation of GS site 3a ϩ b on R d that could be explained by acipimox by the decrease in the effect estimate when treatment entered the model. The model was adjusted for insulin infusion. For the analysis, the procedure lme in R (version 2.1) was used (39) . Results are presented as estimate (95% CI), unless otherwise stated.
RESULTS
Baseline characteristics. Clinical characteristics of subjects are shown in Table 1 . All subjects had lipodystrophy, as indicated by their trunk-to-limb fat ratio, elevated triglycerides (plasma triglycerides Ͼ1.7 mmol/l) (40), and plasma FFA concentration (plasma FFAs in healthy men 292 Ϯ 58 mol/l) (41). All patients received at least one nucleoside analogue, seven received at least one protease inhibitor, and five a nonnucleoside analogue. All patients except one had suppressed HIV RNA. Effect of acipimox on metabolic biochemistry. Basal plasma glucose and insulin concentrations were not different in the placebo and acipimox trials ( Fig. 2A and B) .
Basal plasma FFA concentration was 51.6% (95% CI 43.0 -58.9) lower during the acipimox than during the placebo trial. During stage 1 of the clamp, plasma FFA concentration was reduced 61.3% (53.4 -67.8) in the acipimox trial compared with a 46.2% (35.9 -54.9) reduction in the placebo trial. During stage 2, the clamp plasma FFA concentrations were not reduced further (P Ͻ 0.0001 for treatment effect, P Ͻ 0.0001 for low-dose insulin effect during placebo, P ϭ 0.035 for low-dose insulin effect during acipimox, and P ϭ 0.27 for high-dose insulin effect) (Fig. 2C) . Basal plasma glycerol concentration was 36.5% (95% CI 29.2-43.1) lower during the acipimox than during the placebo trial. During stage 1, plasma glycerol concentration was reduced 58.7% (53.6 -63.3) in the acipimox trial compared with a 43.4% (36.3-49.7) reduction in the placebo trial. During stage 2, plasma glycerol concentrations were not reduced further (P Ͻ 0.0001 for treatment effect, low-dose insulin effect during placebo, and low-dose insulin effect during acipimox and P ϭ 0.89 for high-dose insulin effect) (Fig. 2D) 81 .1% compared with baseline; P ϭ 0.27). The effect of insulin infusion was significant for both the acipimox (P ϭ 0.002) and the placebo (P Ͻ 0.0001) trials (Fig. 3) . .7% compared with baseline). The effect of insulin infusion on R a was significant for both the acipimox and the placebo trials (P ϭ 0.0003) (Fig. 4A) .
Effect of acipimox on glucose

FIG. 2. Plasma glucose (A), insulin (B), FFAs (C), and glycerol (D) levels during the basal stage, low-dose insulin infusion (stage 1), and high-dose insulin infusion (stage 2) after overnight treatment with placebo (E) and acipimox (F). Data are presented as means
Glucose R d increased to a greater extent in the acipimox than in the placebo trial during stage 1 (acipimox: 26 178.3% compared with baseline; P ϭ 0.16). The effect of insulin infusion was significant for both the acipimox and the placebo trials (P Ͻ 0.0001) (Fig. 4B) . Effects of acipimox on regulation of glycogen synthase activity and insulin signaling. Both low and high insulin infusion increased GS activity (I-form) (P Ͻ 0.0001), decreased phosphorylation on GS site 3a ϩ b (P Ͻ 0.01), and increased phosphorylation on both GSK-3␤-Ser 9 (P Ͻ 0.001) and Akt Thr 308 (P Ͻ 0.0001) (Fig. 5A-D ) measured in muscle tissue preparations. In response to acipimox treatment, phosphorylation of GS site 3a ϩ b decreased (treatment effect, P ϭ 0.017) (Fig. 5B) and the percent I-form activity of GS increased (treatment effect, P ϭ 0.01 [log transformed] and P ϭ 0.04 [nontransformed]) (Fig. 5A) . Phosphorylation of GSK-3␤ and Akt did not change in response to acipimox treatment (GSK-3␤: P ϭ 0.06 [nontransformed]; P ϭ 0.05 [log transformed] and Akt Thr 308 : P ϭ 0.42) (Fig. 5C and D, respectively) . Total GS activity was unchanged by both treatment and insulin (data not shown). The effect of acipimox on R d appeared partly explained by increased dephosphorylation of GS 3a ϩ b, as 24% of the effect of GS site 3a ϩ b on R d was due to acipimox treatment.
DISCUSSION
The present study demonstrates that decreasing plasma FFA concentrations and R a palmitate by acipimox treatment increase peripheral insulin-stimulated glucose uptake in HIV lipodystrophy without any influence on hepatic glucose production.
Similar to the observation of Hadigan et al. (12), who treated patients with HIV lipodystrophy with acipimox for 3 months, we found a decrease of ϳ50% in basal levels of circulating FFAs and R a FFAs and an ϳ30% increase in glucose uptake in response to acipimox. The fact that acute and chronic acipimox treatment elicited the same responses with regard to plasma FFA and insulin sensitivity suggests that chronic lipid-induced insulin resistance can be reversed equally by acute and chronic intervention. The present study adds to former studies by pinpointing the effect specifically to glucose uptake and on muscle insulin signaling. During stage 1 (low insulin doses), there was a significant difference between the placebo and the acipimox trials with regard to plasma FFAs, R a palmitate, and R d glucose. During stage 2 (high insulin dose), lipolysis was totally blocked by insulin, which is most likely the reason for no detectable effect of acipimox on glucose metabolism. The response of R a FFAs to acute acipimox during high-dose insulin is similar to the response of R a FFAs to chronic acipimox (12) .
It is, to some extent, surprising that we did not find any effect of acipimox on hepatic glucose production, even during low insulin dose. This finding conflicts with some previous observations (31, 42, 43) using acipimox to suppress lipolysis. Three other studies have demonstrated that acute acipimox treatment decreases basal hepatic glucose (31) and increases hepatic sensitivity to insulin in type 2 diabetic subjects (31, 42, 43) . One explanation for the discrepancy could be that the basal levels of plasma FFAs were higher in the diabetic patients. Taken together, our findings suggest that the nature of hepatic insulin resistance in patients with nondiabetic HIV lipodystrophy may, to some extent, differ from that seen in type 2 diabetes. It is still unknown whether increased hepatic glucose production in HIV lipodystrophy is a result of increased gluconeogenesis or increased glycogenolysis or a combination of both. It could be argued that the patients we selected for the present study did not demonstrate hepatic insulin resistance. However, the subjects had increased R a glucose (8.1 mol ⅐ kg body wt Ϫ1 ⅐ min Ϫ1 ; ϳ6.2 mol ⅐ kg fat-free mass Ϫ1 ⅐ min Ϫ1 ) compared with R a glucose in healthy men (ϳ2.1 mol ⅐ kg fat-free mass Ϫ1 ⅐ min during low insulin dose (3). Inhibition of insulin-stimulated glucose uptake by FFAs is supported by other studies, including experimental designs, where plasma FFA levels were lowered by acipimox (19, 30, 44, 45) or increased by lipid infusions (14,46 -48) . In these studies, the effect on glucose uptake was observed at a high insulin dose (40 -80 mU/m 2 per min). Our study shows that the effect of suppression of FFA levels may, in fact, be more easily detected at lower insulin concentrations (20 mU/m 2 per min).
Patients with HIV lipodystrophy are characterized by having decreased oxidative and nonoxidative glucose disposal (25) (26) (27) . During insulin stimulation, nonoxidative glucose metabolism is thought to primarily represent muscle glycogen synthesis (49) . As expected, insulin administration induced increased phosphorylation of Akt Thr 308 and GSK-3␤ Ser 9 , decreased phosphorylation on GS (site 3a ϩ b), and subsequently increased the activity of GS in both trials. Interestingly, in the response to acipimox treatment, GS activity (%I-form) was greater and phosphorylation of GS (site 3a ϩ b) decreased compared with before treatment. Moreover, acipimox-induced increase in glucose uptake was associated with acipimox-induced improvement of the insulin signaling pathway, although this does not prove causality.
Regulation of GS activity by manipulating FFA concentration is in accordance with previous studies (13) (14) (15) (17) (18) (19) . GSK-3 is a serine/threonine kinase that inhibits GS activity by phosphorylation of GS (50) at sites 4, 3c, 3b, and 3a (51) . However, in our study, we did not find a significant effect of acipimox treatment on phosporylation of GSK-3␤ Ser 9 . This finding is surprising but seems consistent with the observation in rodents that insulinstimulated glycogen synthase activity is inhibited by infusion of lipids independent of deactivation of GSK-3 (24) . In addition, Skurat et al. (50) have previously, in an in vitro study, demonstrated that GS (site 3a ϩ b) can be phosphorylated by unidentified protein kinases, suggesting regulation of GS activity by non-GSK-3-mediated pathways (24, 52) .
Upstream of GSK-3, acipimox treatment correspondingly did not effect phosphorylation of Akt Thr 308 , a marker of Akt activity. Conflicting data on regulation of phosphorylation of Akt by lipids exist. In a study by Kryszynska et al. (23) , intralipid infusion did not change phosphorylation of Akt Thr 308 and Akt Ser 473 despite reduced whole-body insulin-stimulated glucose disposal. In contrast, two other in vivo studies (humans [21] and rats [24] ) find impaired phosphorylation of Akt Thr 308 and Ser 473 in response to lipid infusion. These discrepancies may indicate that the signaling mechanism is different when inducing acute insulin resistance by lipid infusion compared with reversing chronic insulin resistance by acipimox treatment. Furthermore, it cannot be excluded that acipimox itself may directly stimulate glycogen synthesis in skeletal muscle, although no receptors for nicotinic acid in skeletal muscle have been identified (53) . Finally, it is possible that acipimox treatment may lead to improved activation of protein phosphatases regulating GS activity during insulin stimulation. This, however, remains to be investigated.
The present study provides direct evidence that suppression of lipolysis in patients with HIV lipodystrophy improves insulin-stimulated peripheral glucose uptake without influencing hepatic insulin resistance. The increased glucose uptake may in part be explained by increased dephosphorylation of GS (site 3a ϩ 3b), result- 
